Boston, MA – According to filings with the U.S. Securities and Exchange Commission, Pyxis Oncology is raising $22,000,000.00 in a new round of investment. Sources indicate as part of senior management Chief Executive Officer, David Steinberg played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Pyxis Oncology

Pyxis Oncology has unlocked multiple new avenues to restore the potency of dysfunctional immune cells. Pyxis is developing a diverse pipeline of new antibodies to enhance the immune response against cancer, even in tumor types that historically have not responded well to cancer immunotherapies.

To learn more about Pyxis Oncology, visit http://www.pyxisoncology.com/

Contact:
David Steinberg, Chief Executive Officer
617-351-2575

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved